Big Picture – A Deep Dive Examination of Braveheart Investment Group
Braveheart Investment Group Snapshot
Braveheart Investment Group’s strategy is to continue to develop organically, via acquisition, or via joint venture, but always with a clear focus on its specialist areas of equity, debt, and fund management.
Within this, the Group seeks to widen its geographic coverage and add operational expertise and funds under management which are complimentary to its existing activities
The Group provides equity, loan and mezzanine funding to Small and Medium-sized Enterprises (SMEs).
Braveheart's investment portfolio has a strong focus on advanced technology companies, often with links to leading UK universities.
Our management team works closely with investee businesses to support their growth and development.
What we do
Braveheart Investment Group plc was formed in 1997 and has been quoted on the Alternative Investment Market (AIM: BRH.L) of the London Stock Exchange since 2007. Headquartered in Barnsley, Yorkshire.
The Group has funds under management across various regional funds. Braveheart also invests directly into companies with high growth potential and where needed takes a ‘hands-on’ approach to their management. Braveheart seeks to identify new investment opportunities, help them to grow and ultimately exit these investments when timing and valuations are appropriate. Braveheart works closely with high net worth individuals (HNWs), institutional investors and public sector organisations spanning the UK and Europe.
A selection of our portfolio companies, both past and present, is displayed here.
Healthcare equipment & services
Travel & Leisure
Technology hardware & equipment
Cascade has created a technology which uses quantum cascade lasers to provide breakthrough products that create instant DNA type fingerprints of gases, enabling their presence and quantity to be detected. Company acquired by Emerson Group in 2015
mLED was spunout from the University of Strathclyde in 2011. It provides unique solid-state optical micro-projection systems with the potential to provide seamless integration into a variety of applications. Company acquired by Facebook subsidiary in 2016.
A spin-out from Heriot-Watt University, NiTech has invented and patented a unique mixing technology known as the Continuous Oscillatory Baffled Reactor (COBRTM). This technology is for use in a variety of chemical, pharmaceutical, and other process industries.
Formed in 2007, Pyreos has developed a patented thin film pyro-electric ceramic technology for use in a new range of infra-red sensor products. The technology will initially be applied for use in mass market and high value specialist applications such as motion detectors, spectroscopy and infra-red cameras.
Software & computer services
Founded in 1999, Bloxx is an award-winning web filtering company which has developed novel approaches to prevent inappropriate use of the web, both to stop nasty web material from hitting users' desktops, and also to give control over access to other types of websites that impact on user productivity, such as shopping. The company has expanded to a multimillion pound operation with products sold in Europe and North America. The company was acquired in November 2015 by NASDAQ-listed Akamai.
A double spin-out from Edinburgh and Glasgow universities, Dimensional Imaging was the first company to be supported by Braveheart's SMART Equity Scheme. The company provides 3D and 4D image capture systems to the entertainment, medical, and other industries. The company’s 4D capture system has been used on award winning projects, giving animation teams around the world the edge.
Gyrometric has developed a patent protected system of hardware and software to accurately monitor the vibrations in rotating shafts. Warnings generated by this system helps prevent expensive and untimely breakdowns in industry and transport. The company is a spin out from Nottingham Trent University and is based in Nottingham, UK. Its equipment is used to measure the performance of both high-speed and low-speed shafts in a wide variety of applications such as marine engines, wind turbines and industrial machine tools. The Gyrometric monitoring system can be used to protect drive-trains from overload damage, or predict when maintenance is required and hence allows customers to operate at maximum efficiency, saving energy, maintenance and capital costs. By detecting and monitoring minute irregularities in the motion of drive shafts the Gyrometric products predict failure of these shafts and the motors, bearings and couplings attached to them.
Gyrometric already has established sales partners in Germany and Asia and its leading marine OEM customer has been operating the Gyrometric MDS2 technology successfully in the tug boat and cruise liner markets for several years. The company is planning to roll this out to cruise liner operators across the world, where planned maintenance can save them many hundred thousand pounds a day verses a breakdown or delayed departure.
Electronic & electrical equipment
Based in Livingston, Conjunct was formed in 2004 to address the ever-increasing need for higher-bandwidth and higher-speed optical data and communications transmission devices.
Design LED Products has developed and patented technology to embed Light Emitting Diodes (LEDs) within printed light-guide devices. This enables thin, flexible, high efficiency light panels and displays suitable for a range of applications from consumer electronic devices to large area LED lighting and LCD TV backlighting.
Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation market. The company is based in York in the United Kingdom and has developed and patented its innovative ActiPix™ technology for optical imaging and absorbance measurements of fluid samples flowing in capillaries or fluid flow cuvettes. This technology enables researchers to measure the viscosity of drug formulations and the effective size of the active ingredients in these formulations. Paraytec's instruments can also be used to monitor how tablets, gels and creams, release their active ingredients into liquids, including biological media, as well as across membranes such as skin. The use of this technology allows the user to materially speed up drug development efforts by providing data in a real time that would otherwise be unavailable. Paraytec will focus resources on supporting its two license deals, which are progressing well: Malvern Instruments (part of Spectris plc) has incorporated ActiPix™ technology into its own branded instruments, which are now well established in the market place; and Sirius Analytical (part of Pion Inc.) launched its own instrument in the US in late 2016.
Founded in 2005, Traak is developing intelligent self-learning radio frequency identification (RFID) and sensor solutions for the growing RFID sector. RFID technology is commonly used in a wide variety of industries such as retail, transportation, logistics and healthcare.
Pharmaceuticals & biotechnology
EctoPharma is virtual pharmaceutical company focused on commercialising patented technologies by developing new medicines which address unmet therapeutic needs in major markets. The company is currently conducting R&D work into a novel gene therapy which may have the potential to help the treatment of several forms of cancer.
Kirkstall has developed Quasi Vivo™, a system of interconnected chambers for cell and tissue culture in laboratories. Its patented technology is used by researchers in academia and drug development companies to maintain living cells in a nutrient flow. The technology, often referred to as 'organ on a chip', provides a way to model the behaviour of multiple human organs interconnected by a flow system that mimics the flow of blood in the body. Introducing flow into cell culture has the benefit that the cells are more active and respond to stimuli (such as dosing with a drug or chemical) in a way that is more predictive of what is likely to happen in a clinical environment.
Kirkstall's products are already being used by researchers in the development of drugs, nutraceuticals, cosmetics and personal care products. By enabling the testing of drugs on living tissue, there is the potential to greatly reduce the need for expensive animal testing and improve the chances of success in human clinical trials.
Trevor has been a strategic investor in equities and real estate for more than 30 years. He is also currently a director of Flying Brands plc and a Non-executive Director of Remote Monitored Systems plc. Trevor joined the Board of Braveheart as a Non-executive Director on 1 April 2014 and was appointed Chief Executive on 24 August 2015.
CEO Strathtay Ventures
Viv is CEO of Strathtay Ventures Ltd, which manages the operational functions and investment portfolio of Braveheart. He has been a fund manager and director at Viking Fund Managers Ltd, the Group's fund management business for several years. Viv joined Inkopo as Director, providing business consultancy to companies across Yorkshire, until it was acquired by Braveheart in 2009. He had previously worked in product development for the automotive engineering sector and international sales management for a Swiss group. He is a Chartered Engineer and has an MBA from Aston University.
Jonathan is currently the senior independent director of Futura Medical plc and non-executive director of Kingswood Holdings Ltd, which are both quoted on AIM. He has worked in the financial services sector for over 20 years with the most recent previous roles including being a director of Hume Capital Securities plc and the CEO of Syndicate Asset Management plc. Jonathan joined the Board of Braveheart as an Executive director with effect from 21 August 2015 and became a Non-executive Director on 3 March 2016
The company's shares commenced trading on AIM on 30 March 2007 and are not traded on any other platform other than AIM. There are no restrictions on the transfer of the company’s shares.
Number of shares in issue: 27,082,565
Shares Percentage of securities not in public hands: 51.15%
The company has been notified that the following shareholders have an interest of 3% or more of the total shares in issue:
|Name||Number||Percentage of issued|
|Trevor E Brown (CEO)||8,075,934||29.82%|
|DC Thomson Ltd||2,258,490||8.34%|
Last updated: 7 May 2019
Braveheart Investment Group plc,
1 Capitol Court,
Capitol Business Park,
Tel: +44 (0) 1738 587555
Fax: +44 (0) 1738 587666
Braveheart Investment Group plc
1 George Square
Tel: +44 (0) 1738 587555
Fax: +44 (0) 1738 587666
90 St Vincent Street
T: +44 (0)141 225 4975
1 George Square
P +44 33 0222 0050
F +44 33 0222 0053
HSBC Bank plc
76 Hanover Street
Fax: +44 (0) 131 456 3201
Nominated Adviser and Joint Broker
Allenby Capital Limited
5 St Helen’s Place
Tel: +44 (0) 203 328 5656
Fax: +44 (0) 203 394 2970
Peterhouse Capital Limited
New Liverpool House
15 Eldon Street
Tel: +44 (0) 20 7469 0930
Fax: +44 (0) 20 7220 9798
Link Asset Services Limited
34 Beckenham Road
Tel: 0871 664 0300*
+44 (0) 208 639 339 (from overseas)
Fax: +44 (0) 1484 601 512
* Calls cost 10p per minute plus network extras, lines are open 8.30am – 5.30pm Mon-Fri.
Email: [email protected]
Old Linen Court, 83-85 Shambles Street, Barnsley, South Yorkshire, S70 2SB
Telephone: 01 226 298 298
Facsimile: 01 226 298 498